Skip to main content

Table 3 Clinical trials with CSF1/CSF1R inhibitors in combination with cancer immunotherapy agents

From: Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy

Class Target Compound/Class Combination partner Clinical phase Sponsor Indication identifier Status/Results Reference
Small molecule CSF1R (and cKIT, Flt3) Pexidartinib (PLX3397, PLX108-01) Pembrolizumab (anti-PD1 mAb) 1/2 Plexxikon/Daiichi Sankyo Solid tumors, malignant melanoma
GIST, NSCLC, ovarian carcinoma, TNBC, SCCHN, UBC, pancreatic cancer, gastric carcinoma, leiomyosarcoma, cholangio carcinoma, CRC (MSS)
NCT02452424 Ongoing [74]
Durvalumab (anti-PDL1 mAb) 1 Astra Zeneca Pancreatic carcinoma, CRC NCT02777710 Ongoing -
CSF1R ARRY-382 Pembrolizumab (anti-PD1 mAb) 1 Array BioPharma Solid tumors, melanoma, NSCLC NCT02880371 Ongoing -
CSF1R BLZ945 PDR001 (anti-PD1 mAb) 1/2 Novartis Solid tumors NCT02829723 Ongoing -
Monoclonal antibody CSF1R Emactuzumab (RG7155) Atezolizumab (anti-PDL1 mAb) 1 Roche Solid tumors, TNBC, gastric cancer, soft tissue sarcoma, UBC, ovarian cancer, NSCLC, melanoma NCT02323191 Ongoing -
RG7876 (CD40 agonist mAb) 1 Roche TNBC, gastric cancer, mesothelioma, CRC, melanoma, pancreatic cancer NCT02760797 Ongoing -
CSF1R AMG820 Pembrolizumab (anti-PD1 mAb) 1 Amgen Solid tumors NCT02713529 Ongoing -
CSF1R Cabiralizumab (FPA008) Nivolumab (anti-PD1 mAb) 1 FivePrime/BMS Solid tumors, NSCLC, SCCHN, pancreatic cancer, ovarian cancer, RCC, GBM NCT02526017 Ongoing [75]
CSF1R IMC-CS4 (LY3022855) Durvalumab (anti-PDL1 mAb) or Tremelimumab (anti-CTLA4 mAb) 1 Eli Lilly Solid tumors NCT02718911 Ongoing [76]
CSF1 MCS110 PDR001 (anti-PD1 mAb) 1/2 Novartis Solid tumors, TNBC, pancreatic cancer, melanoma, endometrial cancer NCT02807844 Ongoing -
CSF1 PD-0360324 Avelumab (anti-PDL1 mAb) 1 Pfizer Solid tumors NCT02554812 Ongoing -
  1. CRC colorectal cancer, CSF1 colony-stimulating factor 1, CSF1R colony-stimulating factor 1 receptor, CTLA4 cytotoxic T-lymphocyte-associated protein 4, GBM glioblastoma, GIST gastrointestinal stromal tumor, mAb monoclonal antibody, MSS microsatellite stable, NSCLC non-small cell lung cancer, PD1 programmed cell death protein 1, PDL1 programmed cell death ligand 1, RCC renal cell carcinoma, SCCHN squamous cell carcinoma of the head and neck, TNBC triple-negative breast cancer, UBC urothelial bladder carcinoma